Gain Therapeutics Phase 1b for GT-02287 enrolls 16 patients; biomarker data now expected Q4 2025

Gain Therapeutics, Inc.

Enrollment reached 16 participants (target 15-20) despite 2-month protocol delay.
Independent DMC recommends continue study unchanged; no serious adverse events reported.
Faster enrollment means 90-day visit and CSF biomarker results earlier in Q4 2025 vs. Q1 2026.
Screening window extended through July 31, 2025; planning to request dosing extension beyond 90 days in Australia.
Long-term toxicology studies near completion; update on dosing extension expected before end of Q3 2025.

item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.